Amikacin therapy for urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli
The Korean Journal of Internal Medicine
;
: 156-161, 2016.
Article
in English
| WPRIM
| ID: wpr-220491
ABSTRACT
BACKGROUND/AIMS:
The number of urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) is increasing. In an outpatient setting, there are limited therapeutic options to treat ESBL-producing pathogens. We evaluated the outcomes of amikacin outpatient parenteral antibiotic therapy (OPAT) for UTIs caused by ESBL-EC in patients not pre-treated with carbapenem.METHODS:
We retrospectively evaluated the outcomes of amikacin OPAT for UTIs caused by ESBL-EC.RESULTS:
From November 2011 to October 2012, eight females, who could not be hospitalized for carbapenem treatment, were treated with amikacin OPAT for nine episodes of non-bacteremic ESBL-EC UTIs. Seven of the eight patients had one or more comorbidities. Of the nine UTI cases, three had symptomatic lower UTIs and six had non-bacteremic upper UTIs. In all of the cases, symptomatic and laboratory improvements were observed following amikacin OPAT. One patient showed a delayed relapse with bilateral microabscesses 3 weeks after treatment cessation; however, a clinical and microbiological cure was eventually reached. All of the patients were able to tolerate amikacin OPAT without any significant nephrotoxicity or ototoxicity.CONCLUSIONS:
Amikacin OPAT represents a feasible therapeutic option for non-bacteremic UTIs caused by ESBL-EC in settings with limited resources.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Time Factors
/
Urinary Tract Infections
/
Urine
/
Beta-Lactamases
/
Remission Induction
/
Drug Administration Schedule
/
Amikacin
/
Microbial Sensitivity Tests
/
Retrospective Studies
Type of study:
Observational study
Limits:
Adult
/
Aged
/
Aged80
/
Humans
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS